Viyash Scientific Q4 FY26 EBITDA Surpasses INR200 Crores

Viyash Scientific reported its strongest quarter with Q4 FY26 EBITDA of INR200 crores, up 64% YoY, and full-year PAT surging 1,324% to INR225 crores.
The company achieved 13.8% revenue growth to INR3,420 crores in FY26, driven by 18% growth in formulations and 8% in API segments.
Management outlined growth strategies including CDMO expansion, companion animal focus, and synergy realization targeting INR125-150 crores annually.
Credit rating upgraded to AA- with strong balance sheet providing flexibility for organic and inorganic growth opportunities in FY27.